Amgen, Inc. Hits New 52-Week High at USD 391.23

Amgen, Inc., a prominent player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 391.23 on March 2, 2026. This achievement underscores the company's robust performance over the past year, with a notable increase of 26.58%, significantly outpacing the S&P 500's performance of 17.36%. With a market capitalization of USD 202,016 million, Amgen stands as a large-cap entity in its industry. The company's price-to-earnings (P/E) ratio is currently at 21.00, reflecting its valuation in relation to earnings. Additionally, Amgen offers a dividend yield of 1.90%, providing a return to shareholders. The company boasts an impressive return on equity of 100.80%, indicating strong profitability relative to shareholder equity. Amgen's financial health is further illustrated by a debt-to-equity ratio of 5.27, suggesting a manageable level of debt in relation to its equity base. The stock's previous 52-week low was recorded at USD 261.43, highlighting the significant upward movement in its price. This milestone reflects Amgen's ongoing strength and position within the competitive landscape of the pharmaceuticals and biotechnology industry.